introduce you people. joining for remarkable cardiovascular for millions morning. stage new of for cost-effective journey paradigm Amarin's a Good at in risk Thank this us lowering to treatment
XX for care a accomplishments I, describe our health changing priorities. followed the hold In period. are will our We Amarin's by recent will CFO, next minutes, After and better. comments, the we comment these Q&A near-term on
in our am respond we questions comments. many Some advance, prepared of sent in which in you thankful, of questions tried for to to I these have
And who of the effectively Before to for Amarin are that Amarin, to progress. invested details, on considerable hard are extended one you or execute your are particular our and the to of shareholders we an commitment we know working jumping period many plan. are new thanks for have in please Whether into making to our all support, you give vision. I want shareholders
approval be We, results of the expanded what we indication of very Vascepa in FDA's anticipate study. the much will forward of for look the to based September an course, upon REDUCE-IT
the investors most REDUCE-IT FDA including cardiovascular our indication based the Vascepa Vascepa that upon The committee, the and results It is seek hear to pervasive benefits is study. meeting multiple this based sNDA launch in of whether or professionals health the upon expanded communicating robust from a for for an ADCOM, discuss for of outcome the care preparing we an days hold are pathways Vascepa, indications, these question publicly consumers. will sNDA. We I of via expanded the advisory to United States, cardioprotective
to As the matter the the today, Amarin, informed if it FDA were if ADCOM not informed focus of has one to Nor meeting, FDA us potential an of be be a has ADCOM meeting. to of plans subject hold the scheduled. intended
FDA advisers, hold that inform to affairs, ADCOM. to FDA regulatory the an experienced not companies not by assured including sponsored that senior required intend is personnel, are does We former it
from months X date than PDUFA for XXXX, less our now sNDA. are the September XX, We
be had The not The believe by FDA in that the to assessment advisers will was REDUCE-IT point conduct able still is sNDA to of ADCOM that could scheduled, impossible complete priority the undertaken FDA FDA process. under Our convened on its before the its preliminary that, review our the will unlikely at its scope FDA. granting status. sNDA not FDA we a one The be The unique, and late review the review review months clock. study that being protocol under while now an the PDUFA its of agreement X is of review time. priority is full this expect review conducting conducted be special its with it it is
timely to our fact, the an process, In seems perspective, orderly and be review in manner. progressing from FDA
will While Amarin FDA addressed date inquiries the promptly September. all FDA's REDUCE-IT with its large in to the was and that the thoughtfully. review reviewing hard is robust and PDUFA ensure accustomed expectation is large advancing Amarin working are that of And a FDA studies. by complete the is to the study,
an all a first-in-class assumption such shared comprehensive have they work and is, through suggest FDA sNDA and review process. various of to work, review our site that of as not should doubt, includes with we or with us. be consistent not for The such opinion, avoidance Vascepa conducting read For a the for other concerns, data visits process in these the review is have analyses, of review not or FDA's timely sNDA comments FDA they our perspectives are sNDA of indication, that seeking our may which of completion the nature the inquiries, and a
As last commence during FDA a sNDA. relatively time. this would wording is of a unproductive before that of final negotiations label focus the the such to determination be a month Amarin the negotiations on late on are available in the process. speculate such review it label at review. reminder, label traditional not Often the A is final It for
our a prepare of for with progress adds commercial cardiovascular Vascepa As know, risk as the seeking consistent cardiovascular you reduction. risk-reduction REDUCE-IT are we confidence study. for we for launch the The in which QX to is we Vascepa, label made
future milestone In million Hopefully, will in quarterly small. QX, product for look this we exceeded revenue time. the $XXX not-too-distant in first the
is we reached important note it to this milestone. However, how
We the sales XXXX to QX. Our the rate is performed REDUCE-IT by sales team see although called from endocrinologists new data-driven our growth strong physicians we results prescribers, to have rates new continues Vascepa cardiologists, led in writers. our encouraging. size sales to from our well, in and productive by be We at and Growth increased of tenured many team was are continue by and past QX representatives plan prescription it half witnessed the witnessed we representatives. other newest prescription also study. reflecting physicians, The on sales becoming of many very representatives most which the of clinical
of our a yet to label, appears we professionals most We limit do have coverage growth limited only continue not not view payers. Vascepa. growth. revenue at health But which outlook However, some for as risk-reduction with opportunity, have to which physicians prescription consistent medical further knowledge this an cardiovascular impedes is some for care and
discuss most Vascepa its upon of As I to direct our in results. Currently, efforts targeted after a will label able expansion promotion will is be broadly more sales clinical with moment, discuss physicians. and we based
approximately had of As June, the REDUCE-IT more sales XX,XXX with representatives our half end about target results X times of published the reached or study. their physicians, the of of
of double size this our the is force. we force for but will therapy, than later While is When as sales this visit number is promotionally progress create of prescriber we new a expectations, targeted our working be a care. patient our the sales physicians with rate lower are of frequency optimal we increasing, not sensitive doubling, standard year, to particularly consistent the by
will cardioprotective XX,XXX effects more the frequency effort of an the more targets in currently. on offices to increasing physicians XX,XXX than currently to to Vascepa. their the between slightly importantly, to compared be physicians We on calls and of intend in More fully and XX,XXX number we U.S. educate of our them increase
We will outreach sponsored interaction, advertising including medical and Vascepa physicians and to peer-to-peer programs, medical seek who via prescribe at digital of multiple media. might meetings, education means, presentations forms reach various other
than greater pancreatitis. deciliter, indication of consumer concern the in limited mg currently primary for are triglyceride XXX we the advertisement which equal advertising, treatment the Vascepa of levels of promotion risk to is per to current for treatment Regarding or
major X refinement people advertising risk expansion, to process can simple Such of for Promotion, millions label of very adverse Upon and approximately we can risk-reduction submit Drug This well based expensive, Office cardiovascular if of but of new indication OPDP, take the iterative for its review messaging disease. be due Vascepa. upon advertisement, of done, approval a to the months. at given X impactful, consumer seeking be Prescription event the to will cardiovascular FDA's should
people events what and States With to want beyond should with in the of therapy, use as the proven, rising standard care. current strokes, United number of available of such a heart disease annual effective, is as risk and addresses deaths which from preventative the attacks cardiovascular Vascepa fear
to are upon build For to we are avoidance replace of seeking of standard not we it. seeking the doubt, care, current
to the Vascepa we cardiovascular-focused With plan and run regard These risk of professionals, risk By non-branded to expansion. interim, on our remains risk advertisements approval. based which cholesterol Vascepa care can For our beyond significantly advertisements run people may reminding promotional health prescription talented cardiovascular of may adding after that working label example, accelerated patients growth the cholesterol their their support OPDP significant professionals after to promotion of regimen, we to advertising advertising, cardiovascular after ready upon consumer while group to launch lower have programs updated exists continue ensure marketing existing OPDP promptly with table for level will launch more. we XX% cholesterol is reduction, XX% to and controlled of In treatment to health set we for management. many on care Vascepa materials to approval advertisements, cardiovascular waiting we management. the to are further educational risk
and expansion Association data and marketing last story other managed available regarding care In Vascepa American addition regarding November, unique, data care was covered sales upon are States. progress managed and deserves making efforts accounts, at label Heart presented supporting them lives educate REDUCE-IT REDUCE-IT managed accounts we patients. top-tier our also to to teams regarding the the the which to plans XXX of be United affairs million cover The nearly therapy, all for have care. as data-driven in to medical current Since efforts our and aggregate, cost-effectiveness those their our expansion, of in compelling. Vascepa's is top-tiered a results cost-effective over visited These
coverage remain. While of managed already Vascepa good, holes is care
to expansion, during label to We more couple have XXXX, in plans, actually prior Blue's continued coverage than see care is Blue managed Shield. of improvements including Blue Cross a incremental that we expected
use not However, to label Vascepa's limit coverage. insurance some continue as expanded to an yet that payers excuse Vascepa is
those plans is Vascepa back the be after expanded. to label will We soon
believe studied evaluate upon ICER in cost-effectiveness reached using that REDUCE-IT preventing cost-effectiveness in its assumption such indication should reductions MACE which clearly cardiovascular the concludes that PCSKX. was it endpoint which from the approved model, I They modeled of deaths. cost that drugs, the review not report of soon risk for it based the they is X heart attacks, our and higher to be notable their which people. favorable week, may We, millions to study The are for assigned most and as have savings the It case as in report strokes therapies advisers, a base drugs, to important the evaluation. ICER point medical high-quality that conclusion scenarios ICER treatment used in draft full should Vascepa attends limited selected to be for and revascularizations add the its Vascepa that will it REDUCE-IT. care help favorable than all Nonetheless, does Vascepa regarding believe, Vascepa. as it in other ICER issued nonprofit to patients convincing for of angina evaluates. for for be the cardiovascular Vascepa the select to rather in all which, by patient reduction, was a of the this used cost-effectiveness also it and ICER, in rating Vascepa. at-risk analysis, assigned evaluated cost-effectiveness of years, cardiovascular from much useful cost-effectiveness of that was Last draft including insurance cost-effective payers, broadly hospitalizations report unstable recent group, is covered of be should health stakeholders,
projects clinical, affairs medical affairs regulatory multiple teams simultaneously. and advance Amarin's to impressively continue
You March, REDUCE-IT New Cardiology, annual witnessed simultaneous of of results which of results of presentation by some past this England Journal at the publication November of in Scientific AHA College with Journal and the late-breaker this Sessions and American accompanied the ACC last were of Medicine of respectively. the
Vascepa coordination persists with further ongoing in submission from Europe the therapy year, of commercialization in to management the with this address European Middle cholesterol Vascepa seeking in risk advancement was Vascepa in of international Vascepa residual approval where study medical We clinical Canada these later approval of conferences of every in the beyond first feedback are targeted on week, Seemingly, studied partners, I Union as our in well track support to as approvals cardiovascular as continue Vascepa In in China. substantial of as that for hear QX REDUCE-IT. East, teams discussed. the
leave used evolved For first is of and results understanding discussions which high-risk be forms, conferences discussions as REDUCE-IT statin such generated peers. beyond of come for by their the Vascepa in beyond these used physicians therapy is now focus Vascepa amongst Vascepa how perspective, many treatment be part, to the patients. therapy enlightened little presented an most In medical on of these witness knowledge clinical have the of should many and practice. It with to an uplifting should with
journals the also gratifying These results made of observations to Vascepa, observations they known importance robust for some that currently fact in is the embrace speak of happy and the are opinion patients. physicians, Vascepa the considering study. few care to them. of are whom see the to too about the to value right not pieces of data known is various Amarin, Similarly, once well know doctors speak it of to cardiovascular to preventative unprecedented The that the but the REDUCE-IT product about their
FDA lot far, the who and of groundbreaking the just clinical who talented and Vascepa, understanding Ameren even have era for making partners cardiovascular about to we've of We at conveying of begun. progress credit Much study next indication of broad of patients tremendously only the much credit in in goes believe come our and we When look have accomplished participated have together Vascepa. we're the physicians a employees health. and we a in we the Vascepa. the and potential yet so introduce thousands as scientists sharing our forward quarter, approval to will new have we to to to served expanded Moreover, received more goes
over With our to that, turn I now discussion the Mike CFO. Kalb,
